Skip to main content
. 2019 Nov 21;50:111–121. doi: 10.1016/j.ebiom.2019.11.004

Table 2.

Patients´ characteristics: CML samples used for in vitro studies.

Patient no. Age (years) Gender Source CML phase BCR-ABL1 mutations Therapy before cell sampling HU IC50 (µM) Palbociclib IC50 (nM) `HU + ponatinib´
#5 64 m PB CP n.t. HU 175 n.t. n.t.
#6.1 48 m PB CP n.t. None 74 n.t. Cooperative
#6.2 48 m PB BP T315I imatinib, dasatinib (dis), nilotinib (dis) 116 31 n.t.
#7 34 m BM CP n.t. None 50 n.t. n.t.
#8 50 m PB CP n.t. None 46 n.t. Cooperative
#9 59 m PB CP n.t. None 73 n.t. n.t.
#10 63 m BM CP n.t. None 75 n.t. Cooperative
#11 54 f PB CP n.t. None 96 n.t. Cooperative
#12.1 48 m BM BP G250E imatinib (res), dasatinib (res), bosutinib (res), ponatinib (res), HU 236 n.t. n.t.
#12.2 48 m BM BP G250E E255V imatinib (res), dasatinib (res), bosutinib (res), ponatinib (res), HU 30 n.t. n.t.
#13 78 f PB BP F317L, L248V, K274del interferon-alpha, imatinib (res), dasatinib (res), bosutinib (res), ponatinib (res), HU, rapamycin 285 n.t. n.t.
#14 55 m BM CP n.t. None 50 n.t. Cooperative
#15 48 f PB CP n.t. None 56 n.t. Cooperative
#16 81 f BM CP n.t. imatinib (dis) 36 5 n.t.
#17 29 f BM CP n.t. None 33 11 n.t.
#18 69 f PB CP n.t. None 41 2 n.t.
#19 71 m BM BP n.t. None 148 338 n.t.
#20 67 m BM CP n.t. None 43 5 n.t.
#21 34 f PB CP n.t. None 72 16 Cooperative
#22 78 m BM CP n.t. None 31 19 n.t.
#23 18 m BM CP n.t. None 14 1 Cooperative
#24 59 f BM CP n.t. None 30 48 n.t.
#25 34 f PB CP n.t. None n.t. n.t. Cooperative

Abbreviations: CML, chronic myeloid leukemia; HU, hydroxyurea; m, male; f, female; PB: peripheral blood; BM: bone marrow; CP, chronic phase; BP, blast phase; n.t., not tested; none, no therapy (diagnostic sample); res, resistant; dis, discontinued due to intolerance; µM, micromolar. Responses of cells to HU, palbociclib and `HU + ponatinib´ were assessed by 3H-thymidine uptake.